PASD1 (PAS domain containing repressor 1) is a cancer-testis antigen that functions primarily as a transcriptional repressor with dual roles in circadian regulation and oncogenesis. The protein contains a PAS domain, leucine zipper, and nuclear localization signal, consistent with its function as a transcription factor 1. PASD1 acts as a nuclear repressor of the CLOCK-BMAL1 heterodimer, suppressing circadian clock function by competing with this core circadian complex 2. In cancer cells, PASD1 promotes tumorigenesis through multiple mechanisms: it enhances STAT3 activity by inhibiting TC45-mediated dephosphorylation of STAT3, leading to increased expression of pro-oncogenic genes and enhanced cell proliferation, migration, and tumor growth 3. The gene shows restricted expression in normal testis but is aberrantly expressed in various malignancies including colorectal cancer, diffuse large B-cell lymphoma, acute myeloid leukemia, glioma, and multiple myeloma 145. Clinical studies demonstrate that PASD1 expression correlates with poor prognosis and advanced tumor stages 5. Its cancer-testis antigen properties and immunogenicity make PASD1 an attractive target for cancer immunotherapy, with several studies demonstrating successful T-cell responses against PASD1 peptides 678.